Thomas Hutson, DO, PharmD, FACP

Thomas Hutson, DO, PharmD, FACP, Baylor University Medical Center

Articles by Thomas Hutson, DO, PharmD, FACP

Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 1, 2024

Drs. Beckermann and Hutson compare the QOL data for tivozanib and belzutifan in patients with relapsed or refractory aRCC.

Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 1, 2024

Drs. Hutson and Beckermann summarize the long-term TIVO-3 data for patients with relapsed or refractory advanced RCC.

Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023

Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.

Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023

Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.